We've noticed that you're using an ad blocker

Our content is brought to you free of charge because of the support of our advertisers. To continue enjoying our content, please turn off your ad blocker.

It's off now Dismiss How do I disable my ad blocker?
❌

How to disable your ad blocker for our site:

Adblock / Adblock Plus
  • Click on the AdBlock / AdBlock Plus icon on the top right of your browser.
  • Click “Don’t run on pages on this domain.” OR “Enabled on this site.”
  • Close this help box and click "It's off now".
Firefox Tracking Prevention
  • If you are Private Browsing in Firefox, "Tracking Protection" may casue the adblock notice to show. It can be temporarily disabled by clicking the "shield" icon in the address bar.
  • Close this help box and click "It's off now".
Ghostery
  • Click the Ghostery icon on your browser.
  • In Ghostery versions < 6.0 click “Whitelist site.” in version 6.0 click “Trust site.”
  • Close this help box and click "It's off now".
uBlock / uBlock Origin
  • Click the uBlock / uBlock Origin icon on your browser.
  • Click the “power” button in the menu that appears to whitelist the current website
  • Close this help box and click "It's off now".
  • ONCOLOGY
  • News
  • Blogs
  • Topics
  • Hematology
  • Image IQ
  • Podcasts
  • Videos
  • Slideshows
  • Conferences

Modern Medicine Network
  • Login
  • Register
Skip to main content
Modern Medicine Network
  • Login
  • Register
Menu
User
Home
  • ONCOLOGY
  • News
  • Blogs
  • Topics
  • Hematology
  • Image IQ
  • Podcasts
  • Videos
  • Slideshows
  • Conferences

SUBSCRIBE: Print / eNewsletter

Taxane-Based Regimen Improves Disease-Free Survival in Early-Stage Breast Cancer

Jul 1, 2002
Volume: 
11
Issue: 
7
  • Breast Cancer, Breast Cancer

LOS ANGELES—Early data from a Breast Cancer International Research
Group (BCIRG) study showed that docetaxel (Taxotere)-based combination
therapy was significantly more effective than standard FAC
(fluorouracil/doxorubicin [Adriamycin]/cyclophosphamide [Cytoxan, Neosar])
for the treatment of early-stage breast cancer (ASCO abstract 141).
Reporting on behalf of BCIRG was its chairman Jean-Marc Nabholtz, MD,
professor of medicine at the University of California at Los Angeles and
director of Cancer Therapy Development at UCLA’s Jonsson Comprehensive
Cancer Center.

The phase III trial compared TAC (Taxotere
[docetaxel]/doxorubicin/cyclophosphamide (TAC) to FAC as adjuvant treatment
for node-positive breast cancer. Dr. Nabholtz said that interim data
analysis with a median follow-up of 33 months showed that TAC reduced breast
cancer recurrence risk by 32% (relative risk 0.68 vs FAC, P = .0011) and
reduced mortality for women with 1 to 3 positive nodes by 54% (P = .006).

"The observed early benefit that TAC provides over FAC in treatment
of node-positive breast cancer is large enough to be of clinical
significance, but final conclusions will require a longer period of
follow-up," Dr. Nabholtz said.

Relapse Risk Reduced

The primary study endpoint is disease-free survival (DFS), assessed by
Cox analysis. This showed a relative risk for TAC/FAC of 0.64 (CI 0.54-0.81,

P
= .0002). "Seventy-four percent of patients were alive and
disease-free at 36 months on FAC and 82% on TAC," Dr. Nabholtz said.

There were 119 recurrences on TAC vs 170 on FAC. This constitutes a 32%
reduction in relapse risk (P = .0011), but planned subset analysis showed
that this improvement was accounted for entirely by better outcomes for
women with three or fewer positive nodes. TAC cut the risk of relapse in
half for these women but did not improve DFS for women with four or more
positive nodes.

Dr. Nabholtz said the investigators were surprised to find that TAC
reduced the risk of relapse almost equally in hormone-receptor positive
(HR+) patients and in those who were hormone-receptor negative (32%
reduction, P = .002, and 38% reduction, P = .005). "It was very
unexpected to see such a difference in a group of patients with positive
hormonal receptor status," he said.

Pages

  • 1
  • 2
  • 3
  • next ›
  • last »

Related Articles

  • OncoMasTR Assay May Help Some Breast Cancer Patients Avoid Chemo
  • RAD51 Linked With PARP Inhibitor Resistance in BRCA-Mutated Breast Cancer
  • HER2+ Breast Cancer Subtypes Resistant to TKIs Through Differing Mechanisms
  • COUNTERPOINT: LHRH Agonists vs Ovarian Ablation for Suppression of Ovarian Function in Premenopausal Breast Cancer Patients
  • POINT: LHRH Agonists vs Ovarian Ablation for Suppression of Ovarian Function in Premenopausal Breast Cancer Patients

Resource Topics rightRail

  • Resource Topics
  • Partner Content
Breast Cancer
Lung Cancer
Prostate Cancer
Colorectal Cancer
Melanoma
Cutaneous T-Cell Lymphomas: Mycosis Fungoides and Sézary Syndrome
3 Keys to Success in the Oncology Care Model

Current Issue

Oncology Vol 32 No 4
Apr 15, 2018 Vol 32 No 4
Digital Edition
Subscribe
Connect with Us
  • Twitter
  • Facebook
  • LinkedIn
  • RSS
Modern Medicine Network
  • Home
  • About Us
  • Advertise
  • Advertiser Terms
  • Privacy statement
  • Terms & Conditions
  • Editorial & Advertising Policy
  • Editorial Board
  • Contact Us
Modern Medicine Network
© UBM 2018, All rights reserved.
Reproduction in whole or in part is prohibited.